Antisense Oligonucleotides- Mechanisms of Action and Rational Design
Presenter: Robert MacLeod (Ionis Pharmaceuticals) Date: February 26, 2020 Recording of the webinar: Click play to view Presenter Biography Robert MacLeod (Ionis Pharmaceuticals) Dr. MacLeod is currently the Vice President Oncology ...
Patient Representative Webinar
Presenter: Daniel O’Reilly and Joseph Ochaba (Oligonucleotide Therapeutics Society) Date: November 19, 2019 Description: With a constantly growing list of oligonucleotide therapies that are entering the clinics, these exciting research molecules-turned-therapeutic strategy are starting to lead the way in treatments for many devastating diseases. ...
Quantification Methods for oligonucleotide therapeutics in serum and tissue
Presenter: Mai Thayer, Amgen, USA Date: October 8, 2019 Description: Oligonucleotides are a quickly evolving modality with strong proof of concept established in the clinic. Despite the clinical success of oligonucleotides, there is still limited understanding of ADME (absorption, disposition, metabolism and excretion) in ...
Advances in SELEX technologies for aptamer selection
Presenter: Günter Mayer, University of Bonn, Germany Date: August 27, 2019 Description: Aptamers are short single-stranded oligonucleotides, selected to interact with target molecules with high affinity and specificity. These characteristics and their versatile applicability, make aptamers universal molecular probes in biotechnological and therapeutic applications. ...
Design of microRNA therapeutics
Presenter: Andrea Kasinski, Purdue University, USA Date: May 15, 2019 Description: MicroRNAs (miRNAs) have emerged as powerful regulators of the genome and, through concerted efforts to identify their function and evaluate their ability to alter cell growth in vitro and in vivo, some have ...
Targeted delivery using aptamers
Presenter: Donald H. Burke/David Porciani, University of Missouri, USA Date: July 25, 2019 Description: Currently, effective cell-targeted delivery tools for oligonucleotide therapeutics are limited. Aptamers that internalize into target cells have been shown to deliver a wide variety of nucleic acid therapeutics, from siRNAs ...
An Overview of Chemical Modifications to CRISPR RNA
Presenter: Keith Gagnon, Southern Illinois University, USA Date: March 21, 2019 Description: CRISPR-based genome editing has emerged as an exciting technology for biomedical and therapeutic applications. Since 2015, a number of studies have explored the effects of chemically modifying the guide RNA components of ...
Pitfalls and problems of miRNA expression analysis
Presenter: Michela Denti PhD, University of Trento, Italy Prof. Denti has an unavoidable commitment that came up on short notice and has arranged for Simone Detassis from her lab to give the webinar in her place. Date: February 12, 2019 Description: microRNAs are intensively ...
Guidelines for Experiments using Antisense Oligonucleotides and Double-Stranded RNAs
Presenter: David Corey PhD, University of Texas, USA Date: 6 December 2018 Description: After decades of research and development, synthetic nucleic acids are beginning to enjoy significant success in the clinic. Approved drugs have increased interest in the field and many basic research studies ...
Oligonucleotide Therapeutics: Technology Evolution for Clinically Relevant Tissue Delivery
Presenter: Anastasia Khvorova, PhD, RNA Therapeutics Institute, University of Massachusetts Medical School Date: 10 September 2018 Description: A decade of progress in oligonucleotide chemistry and formulation development has resulted in several compounds, both siRNAs and antisense, demonstrating robust clinical activity. Based on sequence, these ...
